Skip to content
DataLookout
Menu

NCT04088396

A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)

StatusActive, Not Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 102 versions: 37 with changes below, 13 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial status changed: Recruiting → Active, Not Recruiting
    • Primary and study completion pushed from Sep 2026 to Oct 2026
    • Site details revised at 55 of 55 sites
    v101
  2. Minor Site details revised at 5 of 55 sitesv100
  3. Minor Site details revised at 16 of 55 sitesv99
  4. Minor Study sites: 56 to 55v98
  5. Minor Study sites: 57 to 56
    • Primary and study completion dates pushed to Sep 2026
    v97
Show 32 earlier versionsHide 32 earlier versions
  1. Minor Site details revised at 1 of 57 sitesv96
  2. Minor Study sites: 58 to 57v95
  3. Minor Site details revised at 1 of 58 sitesv94
  4. Minor Site details revised at 40 of 58 sitesv92
  5. Minor Study sites: 59 to 58v91
  6. Minor Study sites: 67 to 59v90
  7. Minor Site details revised at 2 of 67 sitesv89
  8. Minor Study sites: 65 to 67v87
  9. Minor Eligibility criteria expanded, about 10 wordsv86
  10. Minor Primary completion date: Oct 2025 to Apr 2026
    • Study completion date: Oct 2025 to May 2026
    • Eligibility criteria revised
    v85
  11. Minor Study sites revised (65)v84
  12. Minor Site details revised at 2 of 65 sitesv83
  13. Minor Study sites: 64 to 65v82
  14. Notable Enrollment target: 103 to 58v81 Show 8 more changesShow less
    • Primary endpoint revised
    • Study sites: 65 to 64
    • Primary and study completion dates: Oct 27, 2025 to Oct 2025
    • Interventions: Baricitinib (Drug), Placebo (Drug) to Baricitinib (Drug), Tocilizumab (Drug)
    • Eligibility criteria expanded, about 49 words
    • Secondary endpoints: 8 to 7
    • Study arms: 2 to 3
    • Study title expanded, about 4 words
  15. Minor Study sites: 21 to 65v80
  16. Minor Study sites: 65 to 21v78
  17. Notable Primary and study completion dates: Aug 7, 2023 to Oct 27, 2025
    • Study sites: 67 to 65
    v77
  18. Minor Study sites: 66 to 67v76
  19. Minor Site details revised at 2 of 66 sitesv75
  20. Minor Site details revised at 2 of 66 sitesv66
  21. Minor Site details revised at 1 of 66 sitesv65
  22. Minor Site details revised at 1 of 66 sitesv64
  23. Minor Study sites: 69 to 66v63
  24. Minor Site details revised at 2 of 69 sitesv62
  25. Minor Site contacts updated at 1 of 69 sitesv60
  26. Minor Study sites: 68 to 69v59
  27. Minor Study sites: 67 to 68v58
  28. Minor Study sites: 66 to 67v57
  29. Minor Study sites: 65 to 66v56
  30. Minor Site contacts updated at 1 of 65 sitesv55
  31. Minor Eligibility criteria shortened, about 61 words
    • Site contacts updated at 2 of 65 sites
    v54
  32. Minor Study sites revised (65)v53
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Percentage of Participants Achieving Adapted Pediatric American College of Rheumatology 30 Responder Index (PediACR30) Response Criteria at Week 12
Timeframe: Week 12

Secondary (7)

Percentage of Participants Achieving Adapted PediACR30 Response Criteria at Week 24
Percentage of Participants with Inactive Disease
Percentage of Participants with Minimal Disease Activity
Change from Baseline in Juvenile Arthritis Disease Activity Score (JADAS)-27
Change from Baseline in Arthritis-Related Pain Severity as Measured by the Childhood Health Assessment Questionnaire (CHAQ) Pain Visual Analog Scale (VAS) Item
Show 2 moreShow less
Pharmacokinetics (PK): Maximum Plasma Baricitinib Concentration at Steady-State (Cmax, ss)
PK: Area Under the Baricitinib Concentration-Time Curve at Steady-State (AUC, ss)

Arms and interventions

Cohort 1 BaricitinibExperimental

Baricitinib given orally.

Cohort 1 TocilizumabActive comparator

Tocilizumab given Subcutaneously (SC).

Cohort 2 BaricitinibExperimental

Baricitinib given orally.

Drugs: Baricitinib, Tocilizumab

Sites

55 sites in 14 countries

Italy 8, Japan 7, Spain 6, Brazil 5, France 5, Mexico 5, United Kingdom 5, Israel 3, Poland 3, Argentina 2, Czechia 2, Turkey (Türkiye) 2, Belgium 1, India 1